Theratechnologies Inc T.TH

Silver lining

[SABBOBCAT]

The stock price doesn't reflect any value for oncology so we have nothing to lose... Right???? Tomorrow is going to be rough

[SPCEO1]

Tomorrow will be rough but there really never has been any value given to cancer, so with lower costs during the pause, earnings should be better. And only one analyst, the most recent one from Jones, had ascribed any value for cancer. So, technically, he should be the only one lowering his price target. Somehow, the others will likely do so also anyway.  It was suspicious that they had a

[Wino115]

Real bummer. We understood the treatment population was a very difficult population to treat and could have numerous issues to deal with, and that seems to be the case where their issues came to the fore before efficacy came about. I was hoping they were getting patients more in line with 3 or 4L kind of treatment levels where Sort1 is overexpressed and they have more than a 3 month outlook. No

[PWIB123]

Why on earth they haven't already announced a conference call update tomorrow morning is beyond me.

[Bucknelly21]

Because they arent good at this part of it sane thing thats been going on for years

[Bucknelly21]

Isnt it so fitting for thera to finally get coverage just a couple days ago and then release this, its almost comical 

[Wino115]

Cantor must have been contacted as they reported enrollment likely starting back up in 1Q. Don't know if it's a guess or from discussion. Saying keep the faith at 2x sales.

[scarlet1967]

I agree the portion of shareholders who are invested in the company mostly even entirely for the oncology program would appreciate more detailed information about the protocol amendment, lower more frequent dosing for better delivery of the drug less side effects... Well you don't make those changes based on thin air so why can't they follow up the PR with a conference call explaining the

[jfm1330]

Fooled again by this company. Forget the 4-7 x dose. In ligth of the actual situation, this is very unlikely. And again, the 10% of free docetaxel they claim, we don't know what it is. With the toxicity we see, it is likely that it is more than 10% of the dose injected. Also, I never like docetaxel as a warhead, not powerful enoufgh and too much resistance to it in advanced patient. Also, we

[Wino115]

Not hear to debate since the situation is as it is at the moment. But it seems to me that since the situation around safety was not the normal problem with docetaxal you would see (severe neutropenia) that the issue may not be the free float level of 10% being much higher than they state, but that sort1 is more prevalent in the two areas mentioned (ocular/extremity nerves) and it's being

[jfm1330]

How will they attract somebody for the oncology manager they reupped the job offer a week ago? This is freakin misleading, maybe not intentionally, but it just makes no sense to search somebody to fill this job with the situation they are in now.